Analyst consensus rating
AbCellera Biologics Analyst Rating: Strong Buy
ABCL is rated Strong Buy by 8 analysts with a $17.13 target. As of 2026-08-24.
Direct answer
AbCellera Biologics's consensus rating is Strong Buy.
8 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $17.13.
Forecast evidence checked August 24, 2026.
Get free AbCellera Biologics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $11.32
- Average price target
- $17.13
- High price target
- $30.00
- Low price target
- $9.00
- Low target gap
- -20.5%
- Target upside
- +51.3%
- High target gap
- +165%
- Target range width
- 185.5%
- Consensus rating
- Strong Buy
- Analysts
- 8
- Evidence date
- August 24, 2026
- Valid through
- August 31, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for AbCellera Biologics?
AbCellera Biologics has a verified Strong Buy consensus. The same dataset has an average price target of $17.13.
How far are AbCellera Biologics's low and high targets from the recorded price?
The low target implies -20.5%, while the high target implies +165%.
How many analysts are included in AbCellera Biologics's consensus?
The verified consensus includes 8 analysts.
How is AbCellera Biologics's target upside or downside calculated?
The average target of $17.13 is divided by the recorded price of $11.32, then one is subtracted to produce +51.3%. This does not guarantee a future return.
When was AbCellera Biologics's analyst forecast verified?
The data was verified on 2026-08-24. The dataset is valid through 2026-08-31.